Asset
QUEMLICLUSTAT
Arcus Biosciences Inc. Common Stock
Revenue
No revenue reported in loaded filings.
Clinical trials (4)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT04104672 | phase1 | active_not_recruiting | 2019-11-06 | 2027-05-01 | Arcus Biosciences, Inc. | A Study to Evaluate the Safety and Tolerability of AB680 in Participants With Gastrointestinal Malignancies |
| NCT04575311 | phase1 | completed | 2020-10-20 | 2021-09-22 | Arcus Biosciences, Inc. | A Study to Investigate the Pharmacokinetic Profile of Oral AB680 in Healthy Volunteers |
| NCT03677973 | phase1 | completed | 2018-10-16 | 2019-08-19 | Arcus Biosciences, Inc. | A Study to Investigate the Safety of AB680 in Healthy Volunteers |
| NCT04660812 | phase1_2 | completed | 2021-05-10 | 2025-09-05 | Arcus Biosciences, Inc. | An Open Label Study Evaluating the Efficacy and Safety of Etrumadenant (AB928) Based Treatment Combinations in Participants With Metastatic Colorectal Cancer. |
FDA applications (0)
This company has no applications containing this asset.